{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-019019","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2022-12-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.136826+00:00","generated_at":"2026-06-20T22:15:09.171608+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"FDA approves TG Therapeutics' BRIUMVI for relapsing multiple sclerosis; launch expected Q1 2023","bullets":["Approval based on ULTIMATE I & II Phase 3 trials showing annualized relapse rate reduction of 59% and 49% vs teriflunomide.","BRIUMVI is the first anti-CD20 mAb for RMS with a 1-hour infusion twice a year after starting dose.","U.S. commercial launch expected in Q1 2023.","Conference call to discuss approval on Dec 29, 2022 at 8:30 AM ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-019019","json":"https://secwatch.observer/filing/0001558370-22-019019.json","markdown":"https://secwatch.observer/filing/0001558370-22-019019.md","text":"https://secwatch.observer/filing/0001558370-22-019019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000155837022019019/0001558370-22-019019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000155837022019019/tgtx-20221228x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T22:15:09.171608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}